Zubeyde Erbayraktar Erbayraktar

Prof. Dr. Zubeyde Erbayraktar Erbayraktar


Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
30 March 2021 in Journal of Basic and Clinical Health Sciences
Verified
Journal Article
Closed access
PDF file
ZEZubeyde Erbayraktar Erbayraktar
Zubeyde Erbayraktar Erbayraktar
Değerli Meslektaşlarımız ve Katılımcılarımız, Sizleri 15-16 Ocak 2021 tarihlerinde çevirim içi olarak gerçekleştireceğimiz ve ana temasını "Pandemi ile Değişen Tıp Eğitimi ile Klinik ve Temel Araştırmalar" olarak belirlediğimiz COVID-19 Pandemisinde Araştırma-Yayın ve Eğitim Süreçlerine Bakış Kongresi’ne davet etmekten büyük bir onur ve mutluluk duymaktayız. Kongremiz Dokuz Eylül Üniversitesi Sağlık Bilimleri Enstitüsü’nün ‘Journal of Basic and Clinical Health Sciences (JBACHS)’ dergisi etkinliği olup, Dokuz Eylül Üniversitesi Bilimsel Araştırma Projeleri ve T.C. Tarım ve Orman Bakanlığı tarafından desteklenmektedir. Kongremiz sağlık alanında eğitim ve araştırma ile aktif olarak uğraşan disiplinler arası bilim insanlarını bir araya getirmeyi ve pandemi döneminde eğitim, araştırma ve yayınlar açısından yaşadığımız farklılıkları değerlendirmeyi amaçlamaktadır. Yükseköğretim Kurulu Üyesi ve Sağlık Bakanlığı Bilim Kurulu Üyesi olan Prof. Dr. Zeliha KOÇAK TUFAN ‘PANDEMİNİN GÖLGESİNDE YÜKSEKÖĞRETİM’ isimli açılış konuşmaları ile bizleri onurlandıracaklardır. Genel konferanslar, tıp eğitimi ile klinik ve temel araştırmalarda yetkin bilim insanları tarafından sunulacaktır. Kongrede sunulan tüm bildirilerin özet metinleri ve yayına kabul edilmiş olan sözel bildirilerin tam metinleri Journal of Basic and Clinical Health Sciences (ESCI- Emerging Sources Citation Index ve ULAKBİM) COVID-19 ek sayısında yayınlanacaktır. T.C. Tarım ve Orman Bakanlığı, Orman Genel Müdürlüğü tarafından kongremizde sözel bildiri sunan, konuşmacı ve kurullarda yer alan hocalarımız adına fidan dikilecek olup sertifikası gönderilecektir. Böylece Geleceğe Nefes olmaya bizler de katkı sağlamış olacağız. İlk defa gerçekleştireceğimiz çevirim içi kongremizin sağlayacağı bilgi paylaşımının COVID-19 pandemisiyle her geçen gün değişen ve adapte olmaya çalıştığımız eğitim, araştırma ve yayın gibi dinamik süreçlere katkısı olacağı düşüncesindeyiz. Sizlerin değerli katkıları kongremizi bilimsel anlamda zenginleştirecek ve farklı kılacaktır. Dokuz Eylül Üniversitesi, Sağlık Bilimleri Enstitüsü, ‘Journal of Basic and Clinical Health Sciences’ Dergisi ailesi olarak sizleri aramızda görmekten mutluluk duyacağız. Saygılarımızla,

7 April 2021 in Biological Trace Element Research
Verified
Journal Article
Closed access
PDF file
ZHZeynep Haşimoğlu
Zeynep Haşimoğlu
ZEZubeyde Erbayraktar Erbayraktar
Zubeyde Erbayraktar Erbayraktar
EÖErdener Özer
Erdener Özer
SESerhat Erbayraktar
Serhat Erbayraktar
TETuğba Erkmen
Tuğba Erkmen

27 May 2021 in Journal of Basic and Clinical Health Sciences
Verified
Journal Article
Open access
ZHZeynep Hasi̇moglu
Zeynep Hasi̇moglu
ZEZubeyde Erbayraktar Erbayraktar
Zubeyde Erbayraktar Erbayraktar
REReşat Serhat ERBAYRAKTAR
Reşat Serhat ERBAYRAKTAR
Aim: Glioblastoma multiforme (GBM) is the most malignant glial tumor. Angiogenesis which provides nutrient and oxygen support to proliferating cells plays an essential role in GBM development, proliferation, and metastasis. The development of antiangiogenetic agents is a promising treatment approach as blood vessels are essential for the vitality of tumor cells. For this purpose, in this study, the effects of bevacizumab on cell viability and apoptosis were analyzed using glioblastoma cells. Material and method: U-87 MG and T98G cells were treated with various concentrations of bevacizumab for 24 hours, 48 hours, and 72 hours. Cell viability was analyzed after administration of bevacizumab. Cytotoxicity was determined using MTT. Apoptosis rate was determined with cell death detection kit. Results: Cell viability analysis showed that when 8 mg / ml bevacizumab was administered to glioblastoma cells for 48 hours and 72 hours, cell proliferation was only 50% compared to proliferation of cells without bevacizumab. Additionally, apoptosis rates for U-87 MG and T98G cell lines treated with various concentrations of bevacizumab for 48 hours and 72 hours showed results similar to those of cell viability. Conclusions: This study showed that while high concentration treatment of U-87 MG cells caused an increase in cell viability in a time-dependent manner, high dose treatment of T98G cells resulted in a decrease in cell viability in a time-dependent manner. This means that some glioblastoma cells can still survive under high doses of bevacizumab. This, in turn, demonstrated that glioblastoma cells developed resistance against bevacizumab.

30 December 2014 in Sinir Sistemi Cerrahisi Dergisi
Verified
Journal Article
Open access
GIGündüz Kadir İsTan
Gündüz Kadir İsTan
ZEZubeyde Erbayraktar Erbayraktar
Zubeyde Erbayraktar Erbayraktar
NGNecati Gökmen
Necati Gökmen
HBHüsnü Alper Bağrıyanık
Hüsnü Alper Bağrıyanık
MKMuge Kiray
Muge Kiray
SESerhat Reşat Erbayraktar
Serhat Reşat Erbayraktar
Objective: We aimed to investigate the neuroprotective efficacy of gabapentin in experimental spinal cord injury. Material and Method: Twenty-four Wistar albino female rats with normal motor activity were studied in four groups. They were anesthesized with 35 mg/kg ketamine plus 5 mg/kg xylazine. Laminectomy alone was performed in the first group (sham, n=3) while laminectomy was performed together with induction of injury in the second group (control, n=7). In the third group (drug, n=7), gabapentin (150 mg/kg, IV) was administered 2 hours after the the onset of injury. In the fourth group (drug, n=7), gabapentin (150 mg/kg, IV) was used 5 minutes before the induction of injury. Spinal cord injury was performed by applying Yaşargil aneurysm clip. Neurobehavioral tests were done in all groups at days 1, 10, 20, and 30. All rats were sacrified at day 30 and tissue samples from the injury site were investigated histologically with the usage of hematoxylin&eosin and anticaspase-3 dyes. Results: According to the results of the neurobehavioral tests and histological evaluations, recovery in gabapentin administered groups was significantly better when compared with the others Also, results of the fourth group was significantly better than those of the third.Conclusion: Administration of gabapentin was found to improve neurobehavioral and histological recovery from spinal cord injury in rats.

28 February 2017 in Turkish Journal of Biochemistry
Verified
Journal Article
Closed access
PDF file
ZEZubeyde Erbayraktar Erbayraktar
Zubeyde Erbayraktar Erbayraktar
ZÖZeynep Önkal
Zeynep Önkal
KGKemal Kürşad Genç
Kemal Kürşad Genç
Sermin GencSermin Genc
Sermin Genc
Objective: Erythropoietin (EPO) is widely used for treatment of anemia associated with different diseases; however, its adverse effects limit its use in clinical practice. Therefore, understanding the effects of EPO at the molecular and cellular level is crucial to adjust treatment regimes, and to develop non-hematopoietic EPO derivatives. In this study, we used a proteomics approach to identify how EPO treatment modifies the cellular proteome. Methods: SH-SY5Y neuroblastoma cells were used as the model system to analyze the effects of EPO treatment at different time points (24 h and 48 h). Proteomic analysis revealed changes in 74 proteins after EPO treatment. Following proteomics analysis, Reactome pathway analysis were carried out to identify the affected cellular pathways. Results: According to results, EPO alters the levels of 74 protein species (40 were increased, 34 were decreased). The levels of 35 proteins were changed by 24 h EPO incubation, whereas 17 protein species were altered by 48 h EPO incubation. Levels of 22 protein species were altered by both of the incubation periods (24 h and 48 h). Conclusion: Overall, our results suggest that EPO mainly affects protein species in glucose metabolism, protein and RNA metabolism, cytoskeletal proteins, and mitochondrial protein species.

23 September 2026 in AAPS PharmSciTech
Verified
Journal Article
Closed access
PDF file
AÜAyşe Ünal
Ayşe Ünal
GAGüliz Ak
Güliz Ak
HYHabibe Yılmaz
Habibe Yılmaz
TKTuğba Karakayalı Kavruk
Tuğba Karakayalı Kavruk
AEAyça Erek
Ayça Erek
SSSenay Hamarat Sanlier
Senay Hamarat Sanlier